IGM BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.7 USD | +3.19% |
|
+43.70% | +16.73% |
| Apr. 17 | IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets | MT |
| Apr. 17 | IGM Biosciences, Inc. Announces Refocusing of Sanofi Collaboration | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,165 | 2,818 | 952.1 | 728.5 | 485.3 | 554.2 | - | - |
| Enterprise Value (EV) 1 | 1,165 | 2,818 | 722.6 | 301.3 | 147.6 | 386.3 | 384.3 | 351.5 |
| P/E ratio | -7.95 x | -33.3 x | -5.95 x | -3.2 x | -1.76 x | -2.89 x | -3.24 x | -4.05 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 681 x | 228 x | 183 x | 45.2 x | 10 x |
| EV / Revenue | - | - | - | 282 x | 69.3 x | 127 x | 31.4 x | 6.37 x |
| EV / EBITDA | - | - | -4.49 x | -1.36 x | -0.58 x | -1.83 x | -1.7 x | -1.79 x |
| EV / FCF | -24.6 x | -33.2 x | -5.25 x | -18.8 x | -0.72 x | -2.25 x | -1.92 x | -1.7 x |
| FCF Yield | -4.07% | -3.01% | -19% | -5.33% | -139% | -44.4% | -52% | -58.9% |
| Price to Book | - | - | 4.04 x | 2.46 x | - | 2.29 x | 3 x | 3.02 x |
| Nbr of stocks (in thousands) | 30,536 | 31,922 | 32,462 | 42,827 | 58,394 | 58,953 | - | - |
| Reference price 2 | 38.16 | 88.29 | 29.33 | 17.01 | 8.310 | 9.400 | 9.400 | 9.400 |
| Announcement Date | 3/26/20 | 3/30/21 | 3/29/22 | 3/30/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 1.069 | 2.13 | 3.036 | 12.25 | 55.21 |
| EBITDA 1 | - | - | -160.8 | -221.9 | -255.2 | -210.9 | -226.7 | -196.3 |
| EBIT 1 | -44.5 | -83.28 | -165.3 | -228 | -263.5 | -212.3 | -227.6 | -218.1 |
| Operating Margin | - | - | - | -21,324.23% | -12,369.06% | -6,991.49% | -1,858.13% | -395.02% |
| Earnings before Tax (EBT) 1 | -43.13 | -81.36 | -165.2 | -221.1 | -245.7 | -199.2 | -222.2 | -211 |
| Net income 1 | -43.13 | -81.36 | -165.2 | -221.1 | -246.4 | -199.8 | -221.8 | -211 |
| Net margin | - | - | - | -20,683.07% | -11,568.83% | -6,580.38% | -1,810.73% | -382.15% |
| EPS 2 | -4.800 | -2.650 | -4.930 | -5.320 | -4.710 | -3.254 | -2.904 | -2.322 |
| Free Cash Flow 1 | -47.45 | -84.8 | -137.6 | -16.06 | -204.6 | -171.5 | -200 | -206.9 |
| FCF margin | - | - | - | -1,502.25% | -9,606.2% | -5,648.68% | -1,632.3% | -374.82% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/26/20 | 3/30/21 | 3/29/22 | 3/30/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 0.366 | 0.331 | 0.372 | 0.522 | 0.448 | 0.509 | 0.651 | 0.7594 | 0.7781 | 0.8188 | 0.8469 |
| EBITDA | - | - | - | - | - | -54.37 | - | -66.04 | -64.5 | - | - | - | - | - |
| EBIT 1 | -44.2 | -50.68 | -51.96 | -59.22 | -60.51 | -56.26 | -63.9 | -68.21 | -66.76 | -65.12 | -53.69 | -52.24 | -52.74 | -53.53 |
| Operating Margin | - | - | - | -16,181.42% | -18,281.57% | -15,124.73% | -12,240.61% | -15,225% | -13,115.91% | -10,002.92% | -7,070.35% | -6,714.04% | -6,441.44% | -6,320.48% |
| Earnings before Tax (EBT) 1 | -44.16 | -50.64 | -51.89 | -58.6 | -58.04 | -52.58 | -59.22 | -64.31 | -61.75 | -60.45 | -50.7 | -48.71 | -49.5 | -50.28 |
| Net income 1 | -44.16 | -50.64 | -51.89 | -58.6 | -58.04 | -52.58 | -59.31 | -64.42 | -61.99 | -60.7 | -50.66 | -49.06 | -49.69 | -50.37 |
| Net margin | - | - | - | -16,009.56% | -17,533.84% | -14,133.33% | -11,361.88% | -14,380.13% | -12,178.59% | -9,323.35% | -6,671.39% | -6,304.64% | -6,069.49% | -5,948.28% |
| EPS 2 | -1.320 | -1.500 | -1.530 | -1.330 | -1.320 | -1.190 | -1.330 | -1.430 | -1.040 | -1.010 | -0.8486 | -0.8157 | -0.8214 | -0.7757 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 3/29/22 | 5/9/22 | 8/8/22 | 11/3/22 | 3/30/23 | 5/12/23 | 8/3/23 | 11/13/23 | 3/7/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 230 | 427 | 338 | 168 | 170 | 203 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -47.5 | -84.8 | -138 | -16.1 | -205 | -172 | -200 | -207 |
| ROE (net income / shareholders' equity) | - | - | -52.7% | -83.1% | -100% | -133% | -355% | -201% |
| ROA (Net income/ Total Assets) | - | - | - | -54.5% | -52.6% | -39.8% | -33.9% | -30.1% |
| Assets 1 | - | - | - | 405.8 | 468.5 | 502 | 654.3 | 701 |
| Book Value Per Share 2 | - | - | 7.250 | 6.910 | - | 4.110 | 3.140 | 3.120 |
| Cash Flow per Share 2 | - | - | - | -0.1400 | -3.670 | -2.420 | -2.510 | - |
| Capex 1 | 2.34 | 17.5 | 13.2 | 10.2 | 12.4 | 13 | 13.5 | 13.7 |
| Capex / Sales | - | - | - | 954.72% | 581.27% | 428.18% | 110.16% | 24.8% |
| Announcement Date | 3/26/20 | 3/30/21 | 3/29/22 | 3/30/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
9.4
USD
Average target price
21.6
USD
Spread / Average Target
+129.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.73% | 554M | |
| -2.63% | 103B | |
| +1.62% | 95.28B | |
| +1.46% | 22.15B | |
| -16.67% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.21% | 16.05B | |
| +5.41% | 13.68B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- IGMS Stock
- Financials IGM Biosciences, Inc.
